

InDex Pharmaceuticals - Q1 2023

Redeye comments on InDex Pharmaceuticals following its Q1 2023 report. We consider the report undramatic and do not make any significant adjustments. Again, we highlight that InDex trades at a notable discount compared to its cash position.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

InDex Pharmaceuticals - Q1 2023